Business

OpGen Inc (NASDAQ: OPGN) Achieve Milestone in Unyvero A30 RQ Platform Program

OpGen Inc (NASDAQ: OPGN) is a precision medicine company attaching the power of molecular diagnostics and bioinformatics to contain infectious diseases. The company announced that its subsidiary Curetis GmbH and its engineering partner had assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform. The completion of assembly marks the key milestone or significant development in the Unyvero A30 program.

Assembly marks the key milestone for the company

The company announced that its subsidiary Curetis GmbH and its engineering partner had assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform. The completion of assembly marks the key milestone or significant development in the Unyvero A30 program. The Unyvero A30 RQ platform is developed to deliver fast and multiplexed testing results in a fully automated sample-to-answer manner of native clinical specimen types. 

The company’s results from the samples collected through swabs or some other simple fluids can be available within thirty minutes. Further, the more complex native specimen results will likely take 45 to 90 minutes, depending on specifics. The platform’s design has been optimized to multiplexing up to 33 analytes (from a single native sample in a fully integrated cartridge).  In addition, the company’s platform can look at the various pieces and test a wide range of DNA and RNA nucleic acid targets.

The platform enables multiplexing and quick results

The company indicated that its platform has a feature of multiplexing and enable the quick outcome. The entire process is cost-effective for the single-use cartridges and instrument system. In addition, the Unyvero A30 platform can also be made available to the third party for their analysis and product portfolio. Further, the portfolio is likely to support or complement the existing portfolio of multiplexing on the current Unyvero A50 platform. The company stated that its collaboration with instrument development has optimized the program and achieved the vital milestone within the prescribed time and in line with plans. 

Leave a Comment

Your email address will not be published. Required fields are marked *

*